AstraZeneca shares rise after positive breast cancer drug trial results
- He revealed that he made progress in stopping this type of breast cancer
- More than two million are diagnosed with breast cancer each year worldwide
AstraZeneca shares rose on Friday after the group reported positive results in a breast cancer drug trial, in which an experimental drug slowed the progression of the disease.
The pharmaceutical giant told shareholders that the drug has produced a “statistically and clinically significant improvement” in slowing a type of breast cancer in trial patients compared to chemotherapy.
Datopotamab deruxtecan (Dato-DXd) was jointly developed by the British-Swedish group and Japanese global healthcare company Daiichi Sankyo.
The drug in question, Datopotamab deruxtecan (Dato-DXd), was jointly developed by AstraZeneca and the Japanese healthcare company Daiichi Sankyo.
The trial focused on patients with hormone receptor (HR)-positive, HER2-low, or HER2-negative inoperable or metastatic breast cancer.
AstraZeneca Stock They rose 2.4 percent to 11,150 pence in afternoon trading on Friday.
Every year, more than two million people around the world are diagnosed with breast cancer.
According to AstraZeneca, HR-positive, HER2-low or negative breast cancer is the most common subtype, accounting for more than 65 percent of diagnosed cases.
Susan Galbraith, executive vice president of oncology research and development at AstraZeneca, said: “Today’s news about TROPION-Breast01 is a significant advance for patients with HR-positive, HER2-low or negative metastatic breast cancer whose tumors have become unresponsive. to endocrine therapy and are currently facing poor outcomes. We are encouraged by these positive outcomes.”
In July, AstraZeneca’s rare diseases division agreed to buy an early-stage gene therapy portfolio from rival drugmaker Pfizer for up to $1 billion.
Ken Takeshita, global head of research and development at Daiichi Sankyo, added: “The positive results from TROPION-Breast01 demonstrate the potential for datopotamab deruxtecan to become an important treatment option for HR-positive, HER2-low or HER2-negative patients.” Breast cancer in the second-line metastatic setting.
“We look forward to realizing the full potential of this TROP2-targeting antibody conjugate in all breast cancer subtypes through our ongoing Phase III program, which includes two trials in patients with triple-negative breast cancer.”
The acquisition announcement came as the group’s first-half operating profit more than tripled to $5 billion, thanks to higher sales margins, lower sales costs and modest growth in operating expenses. research development.
Under the deal, which is expected to close in the third quarter, Alexion Pharmaceuticals will gain access to novel adeno-associated virus (AAV) capsids that have proven to be vital tools in gene therapy and editing.
DIY INVESTMENT PLATFORMS
Easy investing and ready-to-use portfolios
Free Fund Trading and Investment Ideas
Fixed fee investing from £4.99 per month
Social investing with CopyTrader feature
Free financial advice
Affiliate links: If you purchase a This is Money product you may earn a commission. These offers are chosen by our editorial team as we think they are worth highlighting. This does not affect our editorial independence.
Compare the best investment account for you